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OBJECTIVES The objective of the study was to evaluate nitric oxide (NO) mediated regulation of mitochondrial
respiration after implantation of a mechanical assist device in end-stage heart failure.
BACKGROUND Ventricular unloading using a left ventricular assist device (LVAD) can improve
mitochondrial function in end-stage heart failure. Nitric oxide modulates the activity of
the mitochondrial electron transport chain to regulate myocardial oxygen consumption
(MVO2).
METHODS Myocardial oxygen consumption was measured polarographically using a Clark-type oxygen
electrode in isolated left ventricular myocardium from 26 explanted failing human hearts
obtained at the time of heart transplantation.
RESULTS The rate of decrease in oxygen concentration was expressed as a percentage of baseline.
Results of the highest dose of drug are shown. Decrease in MVO2 was greater in LVAD
hearts (n 5 8) compared with heart failure controls (n 5 18) in response to the following
drugs: bradykinin (234 6 3% vs. 224 6 5%), enalaprilat (237 6 5% vs. 223 6 5%) and
amlodipine (243 6 13% vs. 216 6 5%; p , 0.05 from controls). The decrease in MVO2
in LVAD hearts was not significantly different from controls in response to diltiazem (222 6
5% in both groups) and exogenous NO donor, nitroglycerin (233 6 7% vs. 230 6 3%).
Nw-nitro-L-arginine methyl ester, inhibitor of NO synthase, attenuated the response to
bradykinin, enalaprilat and amlodipine. Reductions in MVO2 in response to diltiazem and
nitroglycerin were not altered by inhibiting NO.
CONCLUSIONS Chronic LVAD support potentiates endogenous NO-mediated regulation of mitochondrial
respiration. Use of medical or surgical interventions that augment NO bioavailability may
promote myocardial recovery in end-stage heart failure. (J Am Coll Cardiol 2000;36:
1897–902) © 2000 by the American College of Cardiology
Structural and functional mitochondrial abnormalities have
been described in heart failure with evidence of impaired
oxidative phosphorylation and energy production (1–3).
Nitric oxide (NO) released from vascular endothelium is an
important regulator of mitochondrial respiration and tissue
oxygen consumption (4). Nitric oxide binds reversibly at low
micromolar concentrations to the oxygen binding site of
cytochrome oxidase, the terminal enzyme complex of the
electron transport chain, to decrease tissue oxygen con-
sumption. Under conditions of lowered oxygen availability,
NO can bind with greater affinity to the enzyme and may
help decrease oxygen consumption to match tissue oxygen
supply (5). Heart failure is associated with impaired endo-
thelial NO production (6). Recchia et al. (7) showed that
loss of endogenous NO in canine heart failure is associated
with loss of regulation of myocardial oxygen consumption
(MVO2) and progression from compensated to decompen-
sated heart failure.
Angiotensin-converting enzyme (ACE) inhibitors and
amlodipine can regulate MVO2 by promoting kinin-
dependent NO production in coronary microcirculation
(8,9). However, despite pharmacologic therapy some pa-
tients progress to severely decompensated heart failure,
requiring the implantation of a mechanical assist device as a
bridge to transplant. Ventricular unloading using a left
ventricular assist device (LVAD) has been shown to de-
crease myocardial workload and improve exercise perfor-
mance (10) as well as improve efficiency of mitochondrial
metabolism (11). The role of NO in mediating this regu-
lation has not been previously studied. We proposed the
hypothesis that improved mitochondrial function after me-
chanical circulatory support in heart failure is related, in
part, to augmentation of endogenous NO production. This
hypothesis was tested by measuring MVO2 at baseline and
in response to NO stimulating drugs in LVAD-supported
hearts and by comparing them with hearts with end-stage
heart failure but without LVAD support.
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METHODS
Tissue preparation. Myocardial tissue was isolated from
the left ventricular free wall of hearts harvested from 26
patients with end-stage heart failure at the time of ortho-
topic cardiac transplantation and transported immediately
in iced normal saline. Studies of the human heart were
approved by the institutional review board, and the inves-
tigators were blinded to the identity of the patients. The
myocardium was freed of epicardium, endocardium, con-
nective tissue, fat and large arteries and was cut into 30 to
50 mg segments. The muscle slices were incubated for 2 h
in Krebs-bicarbonate buffer (containing the following in
mM: 118 NaCl, 4.7 KCl, 1.5 CaCl2, 25 NaHCO3, 1.1
MgSO4, 1.2 KH2PO4 and 5.6 glucose) through which 21%
O2/5% CO2/74% N2 (room air) was bubbled continuously.
Experimental protocols. Myocardial oxygen consumption
was measured polarographically using a Clark-type oxygen
electrode (YSI 5331, Yellow Springs Instrument Co. Inc.,
Yellow Springs, Ohio) at 37°C in a stirred bath (YSI 5301)
containing 3 ml Krebs solution buffered with 10 mMol/L
HEPES (pH 7.4). Tissue respiration was calculated as the
rate of decrease in oxygen concentration after the addition
of muscle slices, assuming an initial oxygen concentration of
224 nmol/ml and was expressed as nanomoles of oxygen
consumed per minute per gram of tissue. After measure-
ment of baseline MVO2, cumulative dose-response curves
were generated by the addition of various pharmacologic
agents to separate tissue baths in increasing concentrations.
Approximate observation time for each dose of agent was 5
to 7 min. Succinate, a substrate for the electron transport
chain (1 mMol/L) followed by sodium cyanide, an inhibitor
of cytochrome oxidase, (1 mMol/L) were added at the end
of each experiment to confirm that the change in MVO2
was reversible and was from mitochondrial sources.
The following agents were tested: bradykinin, a stimula-
tor of endogenous NO production (1027 to 1024 M, Sigma,
St Louis, Missouri), enalaprilat, an ACE inhibitor (1027 to
1024 M, Sigma, St. Louis, Missouri), amlodipine and
diltiazem, calcium-channel blockers (1027 to 1025 M,
Pfizer, Groton, Connecticut and Sigma, St. Louis, Mis-
souri, respectively) and nitroglycerin, an exogenous NO
donor (2.5 3 1026 to 2.5 3 1023 M, Parke-Davis, Morris
Plains, New Jersey). To assess the role of endogenous NO,
the above experiments were repeated after preincubation of
the muscle segments with Nw-nitro-L-arginine methyl ester
(L-NAME), an inhibitor of NO synthase (1024 M, Aldrich
Chemical Co., Chicago, Illinois).
Statistical analysis. All results are expressed as mean 6
SEM of percent change in MVO2 from baseline. Data were
analyzed using a two-way repeated measures analysis of
variance, with a Student-Neuman-Keuls post-hoc analysis
to identify which means were different (Sigma Stat, Version
2.03, Jandel Scientific, San Rafael, California). A p value ,
0.05 was considered significant.
RESULTS
Clinical profile. Left ventricular myocardium was obtained
from 26 failing hearts at the time of cardiac transplantation
between March 1997 and July 1999. Eight patients had
LVAD support for a mean period of 96 6 15 days before
cardiac transplantation. The remaining 18 patients without
ventricular assist devices comprised the control heart failure
group. Patients included 20 men and 6 women. Age range
was 18 to 64 years (mean age 5 47 6 4 years). Diagnoses
included idiopathic dilated cardiomyopathy (n 5 11), isch-
emic cardiomyopathy (n 5 6), hypertrophic cardiomyopa-
thy (n 5 2), end-stage complex congenital heart disease
(n 5 5), postpartum cardiomyopathy (n 5 1) and primary
pulmonary hypertension (n 5 1). All patients were in New
York Heart Association class IV and had hemodynamics
consistent with end-stage heart failure. Average values were
as follows: ejection fraction, 20 6 1%, cardiac index, 2 6 0.2
L/min/m2; mixed venous hemoglobin saturations, 50 6 3%.
Clinical characteristics of the patients in the two groups
are shown in Table 1. Hemodynamic data in the LVAD
group reflect hemodynamics before LVAD implantation.
Hemodynamics measured before transplant or LVAD im-
plantation were consistent with severe heart failure in both
groups of patients. After LVAD implantation follow-up
cardiac catheterization data were available in two patients
(one to two months after LVAD). Both these patients
showed hemodynamics consistent with improved cardiac
output, including decrease in pulmonary capillary wedge
pressure from 28 to 3, increase in mixed venous hemoglobin
saturations from 44% to 57% and increase in cardiac index
from 2 to 3 L/min/m2. Further, inotropic support was
successfully discontinued in all eight patients after LVAD
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
L-NAME 5 Nw-nitro-L-arginine methyl ester
LVAD 5 left ventricular assist device
MVO2 5 myocardial oxygen consumption
NO 5 nitric oxide
Table 1. Clinical Characteristics
HF LVAD-HF
Number 18 8





Ischemic cardiomyopathy 3 3
Nonischemic cardiomyopathy 15 5
Ejection fraction (%) 18 6 6 21 6 1
Cardiac index (L/min/m2) 2.2 6 0.3 1.6 6 0.2
Mixed venous saturations (%) 53 6 3 44 6 5
Pretransplant ACE inhibitors 11 (61%) 6 (75%)
Pretransplant inotropes 12/18 0/8
HF 5 heart failure; LVAD 5 left ventricular assist device.
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placement. Six of eight patients were continued on an ACE
inhibitor as the only cardiac medication. Therefore, ventric-
ular unloading with a mechanical assist device was charac-
terized by both clinical and hemodynamic improvement.
MVO2. MVO2 in LVAD and heart failure controls. Baseline
MVO2 was not significantly different in the LVAD group
compared with the control group (195 6 17 nmol/g/min in
LVAD vs. 196 6 11 nmol/g/min in control heart failure).
Cumulative doses of bradykinin, enalaprilat, amlodipine,
diltiazem and nitroglycerin caused concentration-dependent
decreases in oxygen consumption in myocardium from both
groups. However, drugs that promote endogenous NO
synthesis caused a greater reduction in MVO2 in the LVAD
group compared with the control heart failure group. The
rates of decrease in oxygen consumption at the highest dose
in LVAD versus the control group, respectively, with these
drugs were as follows: bradykinin (234 6 3% vs. 224 6
5%, p , 0.05) enalaprilat (237 6 5% vs. 223 6 5%, p ,
0.05), amlodipine (243 6 13% vs. 216 6 5%, p , 0.001)
(Fig. 1). Responses to NO-independent calcium channel
blocker, diltiazem and to exogenous NO donor, nitroglyc-
erin, were not significantly different in LVAD versus the
heart failure group: diltiazem (222 6 5% in both groups),
nitroglycerin (233 6 7% vs. 230 6 3%) (Fig. 2).
Effect of inhibiting NO on oxygen consumption. Re-
sponses to bradykinin, enalaprilat and amlodipine were
significantly attenuated by L-NAME, an inhibitor of NO.
Responses to nitroglycerin and diltiazem were not altered by
L-NAME. Results for the LVAD group are shown in
Figure 3A.
Effect of succinate and cyanide on MVO2. Succinate is an
NAD-independent/FAD-dependent substrate that donates
electrons to the mitochondrial electron transport chain to
stimulate mitochondrial respiration and oxygen consump-
tion. Succinate was added at the end of the highest dose of
each drug. As seen in Figure 3B, the addition of succinate
at the end of each experiment increased oxygen consump-
tion in both groups of hearts confirming that the drugs were
acting on the electron transport chain and that their effect
was fully reversible. Sodium cyanide, an inhibitor of cyto-
chrome oxidase, consistently decreased oxygen consumption
by 60% to 80% in both groups confirming that the changes
in oxygen consumption in response to the drugs were of
mitochondrial origin.
DISCUSSION
This study demonstrated that NO regulates oxygen con-
sumption in failing explanted human hearts. The most
important new finding of the study is that chronic LVAD
support in end-stage heart failure is associated with en-
hanced NO mediated regulation of mitochondrial respira-
tion.
Mitochondrial function in heart failure. Mitochondrial
function may be reduced in heart failure (1–3). Studies from
our laboratory have shown an important role for NO in
regulating mitochondrial respiration in the heart. By regu-
lating mitochondrial respiration, NO may help match tissue
oxygen consumption to availability. This is important in
both physiologic and pathophysiologic states. Inhibition of
NO increases whole body, as well as cardiac, oxygen
consumption (12,13). The ability of blood vessels to syn-
thesize NO is markedly reduced in heart failure secondary to
decreased expression of NO synthase (6,14), and this may
contribute to the progression of heart failure (7).
Recent evidence suggests that chronic ventricular unload-
ing using a mechanical assist device can improve mitochon-
drial function and promote myocardial recovery with rever-
sal of left ventricular remodeling and improvement in
myocyte contraction (15,16). Our results indicate that the
Figure 1. Bradykinin, enalaprilat and amlodipine caused a dose-dependent
reduction in myocardial oxygen consumption in failing human hearts. Left
ventricular assist device HF group (solid circles) showed a greater
reduction in oxygen consumption compared with the control HF group
(open circles). *p , 0.05 from baseline; #p , 0.05 from HF. HF 5 heart
failure; LVAD 5 left ventricular assist device; MVO2 5 myocardial
oxygen consumption.
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improvement in mitochondrial function after LVADs may
be related, in part, to restoration of NO biosynthesis in
failing hearts.
MVO2 in failing hearts after LVAD. We have previously
shown that ACE inhibitors and amlodipine, a calcium
channel blocker, cause kinin-dependent NO production in
coronary microvessels to regulate MVO2 (17,18). This
study showed that all the NO dependent agonists: brady-
kinin, enalaprilat and amlodipine, caused significantly larger
reductions in MVO2 in LVAD hearts compared with
controls. This augmentation of response in LVAD-
supported hearts was seen in myocardium from both isch-
emic and nonischemic cardiomyopathy and may have been
secondary to either increased NO availability or to improved
mitochondrial function. However, there was no augmenta-
tion of response when a NO-independent agent, diltiazem,
was used or when NO was supplied exogenously using
nitroglycerin. This indicates that baseline mitochondrial
function was comparable between the two groups and that
enhancement of response in the LVAD group was second-
ary to increased NO availability. This ability to alter
mitochondrial function also suggests that mitochondria may
not be irreversibly damaged in all heart failure and that
restoring NO availability can at least partially restore regu-
lation of MVO2. It is important to note that, despite
augmented response to NO agonists, baseline MVO2 in the
LVAD group was not significantly different from that in
non-LVAD hearts. These estimations were made in iso-
lated myocardium, which is independent of preload and
afterload. In the absence of vascular shear stress, one of the
most potent physiologic stimulators of NO production,
differences in basal NO levels between the two groups may
not have been large enough to cause a measurable change in
basal oxygen consumption.
One of the potential mechanisms of the increase in NO
production after ventricular unloading may be the amelio-
ration of endothelial dysfunction secondary to a decrease in
wall stress. Although we did not measure NO synthase
expression, the rapid (within minutes) decrease in oxygen
consumption and the response to kinin agonists suggests the
involvement of endothelial, rather than inducible, NO
synthase (19).
Lee et al. (11) studied myocardial mitochondrial function
by comparing mitochondrial respiratory rates after LVAD
implantation in heart failure. They reported that the respi-
ratory control index was greater in the LVAD group
compared with controls when NAD-dependent substrates
were used but not with succinate, a NAD-independent
substrate, which represents a less efficient use of oxygen.
Figure 2. (A) Diltiazem and (B) nitroglycerin caused dose-dependent
reductions in MVO2 in failing human hearts. There was no difference in
the response of the LVAD (solid circles) and HF (open circles) groups to
diltiazem or nitroglycerin. *p , 0.05 from baseline. HF 5 heart failure;
LVAD 5 left ventricular assist device; MVO2 5 myocardial oxygen
consumption.
Figure 3. (A) The effect of L-NAME, inhibitor of nitric oxide synthesis,
on MVO2 at the highest doses of drug in the LVAD group is shown.
Nw-nitro-L-arginine methyl ester attenuated the effect of bradykinin,
enalaprilat and amlodipine on oxygen consumption. Nw-nitro-L-arginine
methyl ester had no effect on decrease in oxygen consumption in response
to diltiazem and nitroglycerin. Striped bar 5 LVAD-HF; solid bar 5
1L-NAME. #p , 0.05 from control. (B) Effect of succinate on myocar-
dial oxygen consumption. Succinate, NAD-independent substrate of the
electron transport chain, increased MVO2 in both HF and LVAD-HF
groups, and this response was not different between the two groups.
Amlo 5 amlodipine; BK 5 bradykinin; Dilt 5 diltiazem; Enal 5
enalaprilat; HF 5 heart failure; L-NAME 5 Nw-nitro-L-arginine methyl
ester; LVAD 5 left ventricular assist device; MVO2 5 myocardial oxygen
consumption; NTG 5 nitroglycerin.
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Our study differs in that we did not investigate different
respiratory states since the primary focus of our study was to
evaluate the effect of NO on mitochondrial respiration as a
whole. However, our results with succinate, which demon-
strated a comparable increase in oxygen consumption in
both LVAD and control heart failure groups, are consistent
with the findings of Lee et al. (11). They also indicate that
the decrease in oxygen consumption seen with NO is at the
level of the electron transport chain and is fully reversible,
confirming a modulatory role for NO.
Clinical implications. The ability of LVADs to improve
NO-mediated regulation of MVO2 in failing human hearts
may have important clinical implications. The potential of
LVADs to cause myocardial recovery has prompted research
into the use of VADs as permanent palliation rather than as
a bridge to transplantation. Clinical studies evaluating the
outcome of LVAD explantation, however, have reported
mixed results. While Muller et al. (20) identified 5 of 17
patients with dilated cardiomyopathy in whom LVADs
were successfully explanted with maintenance of normal
cardiac function, Mancini et al. (21) identified only 5 of 111
patients from whom LVADs were successfully explanted.
None of these patients could sustain normal cardiac func-
tion. Therefore, the extent of myocardial recovery after
LVADs is highly variable. Of note, the patients in the
German study not only had a longer duration of LVAD
support but were also maintained on maximal medical
regimen including ACE inhibitors and coenzyme Q10, an
electron transport carrier, both of which have the potential
to improve mitochondrial function. Our study suggests that
if increasing NO production improves regulation of mito-
chondrial function, then concomitant use of NO agonist
drugs with mechanical assist devices may accelerate myo-
cardial recovery in heart failure.
Study limitations. The major limitation of the study was
the lack of suitable controls and the heterogeneity of the
patient population studied. The inability to obtain sufficient
ventricular tissue from the failing hearts at the time of
LVAD implantation prevented paired analysis of the same
heart at the time of transplantation, that is, before and after
ventricular unloading. We, therefore, compared LVAD
supported hearts with non-LVAD hearts. The major con-
cern using this comparison is the heterogeneity of the
patient population studied, especially with regard to etiology
of heart failure and pretransplant exposure to inotropes and
medications. It is important to recognize, however, that,
despite different etiologies, all patients were in decompen-
sated, end-stage heart failure at the time of study. The
pretransplant use of ACE inhibitors and inotropes may
potentially alter NO availability in failing hearts. However,
most patients in both groups were receiving ACE inhibi-
tors. Therefore, ACE inhibitor use was unlikely to account
for the differences between the two groups (Table 1). The
majority of patients with heart failure in the control group
were on inotropic support. Beta-adrenergic stimulation has
been shown to increase NO release in cardiomyocytes (22).
However, since none of the patients in the LVAD group
were on inotropic support after LVAD placement, inotropic
support is unlikely to account for the increased NO avail-
ability in LVAD hearts.
Conclusions. This study demonstrated that ventricular
unloading augments NO-mediated regulation of mitochon-
drial respiration in end-stage heart failure. Use of medical or
surgical interventions that augment NO availability may act
synergistically to optimize myocardial recovery and mito-
chondrial function in end-stage heart failure.
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